Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: Results of a meta-analysis

Respiratory Research

Volumn 7, Issue , 2006, Pages

  Stockley, Robert A ^a   Whitehead, Philip J ^b   Williams, Michael K ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL; SALMETEROL;

ANALOGS AND DERIVATIVES; HUMAN; META ANALYSIS; PLACEBO EFFECT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ALBUTEROL; BRONCHODILATOR AGENTS; HUMANS; PLACEBO EFFECT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 34548021573     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-7-147     Document Type: Article

References (46)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease NHLBI/WHO workshop report. Publication Number 2701 2001, National Institutes of Health, National Heart Lung and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease (GOLD).
2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
3. Wildman M, Groves J, Walia S, Stableforth D, Ayres J. Hospitalised COPD exacerbations: survival and univariate outcome predictors, 36-month follow-up [abstract]. Am J Respir Crit Care Med 2002, 165(2 pt 2):A272.
4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999, 21:576-591. 10.1016/S0149-2918(00)88310-1, 10321424.
5. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504. 10.1016/S0140-6736(96)07492-2, 9167458.
6. CPMP/EWA/562/98 Points to consider on clinical investigation of medicinal products in the treatment of patients with chronic obstructive pulmonary disease (COPD). 1999, CPMP/EWA/562/98.
7. van Noord JA, de Munck DRAJ, Bantje T, Hop WCJ, Akveld MLM, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000, 15:878-885. 10.1034/j.1399-3003.2000.15e11.x, 10853852.
8. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled β2 adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:1087-1092.
9. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965. 10.1378/chest.115.4.957, 10208192.
10. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997, 10:815-821.
11. Mahler DA, Wire P, Horstman D, Change CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1084-1091. 10.1164/rccm.2112055, 12379552.
12. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate 250 mcg/salmeterol 50 mcg combined in the Diskus inhaler for the treatment of chronic obstructive pulmonary disease. Chest 2003, 124:834-843. 10.1378/chest.124.3.834, 12970006.
13. Chapman KR, Arvidsson P, Chuchalin AC, Dhillon DP, Faurshou P, Goldstein R, Kuipers AF. The addition of salmeterol 50 mcg bid to anticholinergic treatment in patients with COPD: a randomized placebo controlled trial. Can Respir J 2002, 9:178-185.
14. Calverley PMA, Pauwels R, Vestbo J, Jones P, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
15. Stockley RA, Chopra NL, . Rice on behalf of the SMS40026 Investigator group Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006, 61:122-128. 10.1136/thx.2004.033266, 16443706, Rice on behalf of the SMS40026 Investigator group.
16. Stockley R, Davis EA, Sondhi S, Rice L. Salmeterol provides sustained health status improvement over 12 months in patients with COPD [abstract]. Eur Respir J 2002, 20(suppl 38):241s.
17. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995, 152:702-706. American Thoracic Society.
18. Siafakas NM, Vermiere P, Pride NB, Paoletti P, Gibson J, Howard P. Optimal assessment and management of chronic obstructive pulmonary disease. The European Respiratory Society Task Force. Eur Respir J 1995, 8:1398-1420. 10.1183/09031936.95.08081398, 7489808.
19. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000, 117:398S-401S. 10.1378/chest.117.5_suppl_2.398S, 10843984.
20. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991, 85:25-31.
21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
22. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung diseases. Thorax 1987, 42:773-778.
23. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989, 10:407-415. 10.1016/0197-2456(89)90005-6, 2691207.
24. Mapel D, Pearson M. Obtaining evidence for use by healthcare payers on the success of chronic obstructive pulmonary disease management. Respir Med 2002, 96(Suppl C):S23-S30. 10.1016/S0954-6111(02)80031-2, 12199488.
25. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 2003, 123:1817-1824. 10.1378/chest.123.6.1817, 12796155.
26. Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract 2006, 60:415-421. 10.1111/j.1368-5031.2006.00849.x, 16620353.
27. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003, 97:1014-1020. 10.1016/S0954-6111(03)00131-8, 14509555.
28. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital readmission in patients with chronic obstructive pulmonary disease. Thorax 1997, 52:67-71.
29. Spencer MD, Williams A. The health status burden of exacerbations in COPD measured using the EQ-5D [abstract]. Eur Respir J 2002, 20(Suppl 38):249s.
30. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
31. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852. 10.1136/thorax.57.10.847, 12324669.
32. Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Felez MA, Sunyer J, Anto JM. Risk factors for hospitalisation for a chronic obstructive pulmonary disease exacerbation - EFRAM study. Am J Respir Crit Care Med 2001, 164:1002-1007.
33. Almagro P, Calbo E, Ochoa de Echaguen A, Barriero B, Quintana S, Heredia JL, Garau J. Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448. 10.1378/chest.121.5.1441, 12006426.
34. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P. Effect of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA 1994, 272:1497-1505. 10.1001/jama.272.19.1497, 7966841.
35. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320:1297-1303. 27372, 10807619, 10.1136/bmj.320.7245.1297.
36. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001, 18:914-920. 10.1183/09031936.01.00216501, 11829096.
37. Van der Molen T, Pieters W, Bellamy D, Taylor R. Measuring the success of treatment for chronic obstructive pulmonary disease - patient, physician and healthcare payer perspectives. Respir Med 2002, 96(Suppl C):S17-S21. 10.1016/S0954-6111(02)80030-0, 12199487.
38. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002, 19:393-404.
39. Cazzola M, Donner CF. Long-acting β2-agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000, 60:307-320. 10.2165/00003495-200060020-00005, 10983735.
40. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. JGen Intern Med 2006, 21:1011-1019. Erratum in: J Gen Intern Med 2006, 21: 1131..
41. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, . SMART Study Group The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26. Erratum in: Chest 2006, 129: 1393., 10.1378/chest.129.1.15, 16424409, SMART Study Group.
42. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006, 144:904-912.
43. Anderson R, Feldman C, Theron AJ, Ramalfi G, Cole PJ, Wilson R. Anti-inflammatory membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br J Pharmacol 1996, 117:1387-1394.
44. Johnson M, Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 2001, 120:258-270. 10.1378/chest.120.1.258, 11451847.
45. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol & Fluticasone 50/250 mcg bid in combination provides a better long-term control than salmeterol 50 mcg bid alone and placebo in patients already treated with theophylline. Pulm Pharmacol Ther 2003, 16:241-246. 10.1016/S1094-5539(03)00065-8, 12850128.
46. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003, 58:399-404. 10.1136/thorax.58.5.399, 12728159.